A Framework for Moment of Transition Tissues Made from Stem Cells and Microphysiological Systems

Charlotte Lewis^*
*Correspondence: Charlotte Lewis, Departments of Pathology, Cell Biology, University of Perth, Australia, Email:

Introduction

Metastasis is the main factor in almost all cancer-related fatalities. These disseminated malignancies continue to be incurable because the protective environment of the metastatic niche restricts the effectiveness of cancer therapy. The course of metastatic disease is still poorly understood because there aren't many appropriate model systems. We suggest an all-human micro physiological system for examining cancer behaviour in the liver metastatic habitat in order to fill this information gap. A 3D technology called the Liver Chip now in use models the hepatic niche. It closely resembles micrometastases and is made up entirely of human parenchymal and nonparenchymal cells. This strategy also permits real-time evaluation of humanspecific signals and monitoring of micrometastasis [1].

Description

With the use of programmable microdispensers, it is being utilised to examine the effects of both established and experimental medications on micrometastases in conditions that mimic diurnal variations in hormone levels, dietary intake, and mild inflammatory states. These signals have an impact on the cues that trigger the responses of tumour cells. The following signalling groups are being investigated: gut microbiome responses to inflammatory signals, cortisol, the stress hormone, and glucose/insulin responses. As determined by urea, antitrypsin, fibrinogen, cytochrome P450, and damage, the system is currently capable of supporting functioning hepatocytes for at least 15 days. Preliminary research reveals that a minority of breast cancer cells encounters growth inhibition. Breast cancer cell lines easily integrate into the hepatic niche without causing detectable tissue damage. Map Technology is also utilised to analyse cellular crosstalk and represent communication networks in the early microenvironment of micrometastases, in conjunction with systems biology modelling. By elucidating the paracrine effects of hepatic and metastatic cells and assessing pharmacological efficacy for metastasis, this model is anticipated to identify new therapeutic alternatives for metastasis [2].

The main reason for cancer-related deaths is metastasis. The molecular processes that enable cancer cells to spread from a primary site to secondary organs are what lead to metastases. Cells from the underlying tumour can emigrate through extravasation into the parenchyma of a distant organ after intravasation into the circulation. Successfully dispersed cells may either proliferate right away or remain dormant for years or decades as minute or pre-malignant micrometastases before becoming clinically evident. This is particularly alarming in the case of breast cancer, where up to 30% of women with early stage breast cancer will later recur with metastatic disease, despite the fact that the main tumour is typically effectively treated. Due to the widespread spread of metastatic tumours limitations of contemporary one of the main obstacles to the development of cancer medicines that target micrometastases is model systems [3,4]. Because they frequently only provide endpoint assessments in addition to issues pertinent to the human context, animal models are inappropriate for this type of research.

Despite the frequent use of immunocompromised mice models, studies have revealed that immune systems play a crucial role in the micrometastatic microenvironment. Syngeneic animal studies that use cytokine and metabolic differences between species are not entirely indicative of human health. Current 2D culture methods do not have key elements that influence tumour behaviour during in vitro culture studies, such as 3D design to provide tissue depth for tumour intercalation, functional elements, such as fluid flow and oxygen content management, and do not provide protracted culture. Additionally, there is a noteworthy dearth of models that can replicate micrometastasis and assess medication efficacy, toxicity, and metabolism. Several researchers have employed organotypic cultures in bioreactors as research tools to overcome these challenges [5].

Conclusion

The liver is a suitable organ system for investigating both the effectiveness of cancer therapy and micrometastasis. First of all, it is a common site for the metastasis of several carcinomas, including melanomas, breast, lung, colon, prostate, and breast. Depending on the type of primary tumour, 30–70% of cancer patients have hepatic metastases. Second, medication activation and detoxification occur mostly in the liver, which is significant for assessing therapeutic efficacy and minimising side effects in cancer therapy. Additionally, there is proof that metastatic illness changes liver function, which may increase toxicity and change an agent's ability to combat a tumour.

Conflict of Interest

None.

References

1. Clark, Amanda M, Sarah E. Wheeler, Donald P. Taylor and Venkateswaran C. Pillai, et al. "A microphysiological system model of therapy for liver micrometastases."Exper Bio Medi239 (2014): 1170-1179.

Google Scholar, Indexed at, Crossref

2. Chen, Nan, Mieradilijiang Abudupataer, Sisi Feng and Shichao Zhu, et al. "Engineering a human pluripotent stem cell-based in vitro microphysiological system for studying the metformin response in aortic smooth muscle cells."Front Bioeng Biotechnol9 (2021): 190.

Google Scholar, Indexed at, Crossref

3. Birla, Ravi K and Stuart K. Williams. "3D bioprinting and its potential impact on cardiac failure treatment: An industry perspective."APL Bioeng4 (2020): 010903.

Google Scholar, Indexed at, Crossref

4. Lock, Roberta, Hadel Al Asafen, Sharon Fleischer and Manuel Tamargo, et al. "A framework for developing sex-specific engineered heart models."Nat Rev Mat7 (2022): 295-313.

Google Scholar, Indexed at, Crossref

5. Marx, Uwe, Tommy B. Andersson, Anthony Bahinski and Mario Beilmann, et al. "Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing."Altex33 (2016): 272.

Google Scholar, Indexed at, Crossref